For the three months ended June 30, the point-of-care infectious disease diagnostics firm posted $4.1 million in total revenues, up from $3.3 million in Q2 2016.
The CE-marked test enables health professionals to distinguish between HIV-1 and HIV-2, and runs on the fully automated Cobas 6800/8800 systems.
OraSure is experiencing strong international demand for its HIV self-test that's offsetting declining sales growth in the domestic HIV segment.
University of Washington scientists found that by adding a material first isolated from shellfish, they could increase the sensitivity of standard bioassays by up to 1,000 times.
The foundation will provide funding of no more than $20 million over the four-year term of the deal, and no more than $6 million each year.
The fourth-generation assay is for the in vitro qualitative assessment of HIV-1 p24 antigen and antibodies to HIV-1 and HIV-2 in human serum and plasma.
An OpenArray panel designed to simultaneously test for 17 viruses and 13 bacteria and protozoa was able to detect pathogens from human blood donor samples with an accuracy of about 95 percent.
Researchers said it could enable more sensitive and streamlined testing for latent HIV-1 levels, which could in turn improve patient monitoring and treatment.
The firm said that it received a $5.8 million order to supply test components and intermediate product for producing its chromographic DPP HIV 1/2 Assays in Brazil.
The firm said that the test delivers results in minutes and is especially helpful in reducing the transmission of syphilis and HIV from mother to child.